CN105188717B - 卟啉修饰末端树枝状聚合物 - Google Patents

卟啉修饰末端树枝状聚合物 Download PDF

Info

Publication number
CN105188717B
CN105188717B CN201380072874.1A CN201380072874A CN105188717B CN 105188717 B CN105188717 B CN 105188717B CN 201380072874 A CN201380072874 A CN 201380072874A CN 105188717 B CN105188717 B CN 105188717B
Authority
CN
China
Prior art keywords
nanocarrier
nps
cholic acid
peg
pyropheophorbide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380072874.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN105188717A (zh
Inventor
K·S·拉姆
李源培
潘崇贤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN105188717A publication Critical patent/CN105188717A/zh
Application granted granted Critical
Publication of CN105188717B publication Critical patent/CN105188717B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A61K41/0033—Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0082—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion micelle, e.g. phospholipidic micelle and polymeric micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1809—Micelles, e.g. phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1227—Micelles, e.g. phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Inorganic Chemistry (AREA)
  • Pathology (AREA)
CN201380072874.1A 2012-12-12 2013-12-12 卟啉修饰末端树枝状聚合物 Active CN105188717B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261736067P 2012-12-12 2012-12-12
US61/736,067 2012-12-12
US13/803,878 US9642916B2 (en) 2012-12-12 2013-03-14 Porphyrin modified telodendrimers
US13/803,878 2013-03-14
PCT/US2013/074762 WO2014093675A1 (en) 2012-12-12 2013-12-12 Porphyrin modified telodendrimers

Publications (2)

Publication Number Publication Date
CN105188717A CN105188717A (zh) 2015-12-23
CN105188717B true CN105188717B (zh) 2018-11-30

Family

ID=50881159

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380072874.1A Active CN105188717B (zh) 2012-12-12 2013-12-12 卟啉修饰末端树枝状聚合物

Country Status (5)

Country Link
US (4) US9642916B2 (enExample)
EP (1) EP2931290B1 (enExample)
JP (1) JP6585504B2 (enExample)
CN (1) CN105188717B (enExample)
WO (1) WO2014093675A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9642916B2 (en) 2012-12-12 2017-05-09 The Regents Of The University Of California Porphyrin modified telodendrimers
KR101421974B1 (ko) * 2013-04-17 2014-07-24 한양대학교 산학협력단 그래핀 옥사이드/담즙산 또는 그의 염 코팅층을 포함하는 복합 분리막 및 그 제조방법
WO2016172635A1 (en) * 2015-04-24 2016-10-27 The Regents Of The University Of California Nanoporphyrin telodendrimers for treatment of vascular abnormalities
US11135309B2 (en) 2015-08-14 2021-10-05 The Regents Of The University Of California Poly(vinyl alcohol) nanocarriers
CN105288623B (zh) * 2015-11-19 2018-06-05 同济大学 一种用于肿瘤治疗的药物及其制备方法
CN106853248B (zh) * 2015-12-09 2020-05-05 首都师范大学 一种光热复合纳米材料及其制备方法与应用
JP6889432B2 (ja) * 2016-04-28 2021-06-18 学校法人甲南学園 樹脂固定ペプチド
EP3512569A4 (en) * 2016-09-15 2020-09-23 The Regents of The University of California ENHANCED HYBRID TELODENDRIMERS
US11559585B2 (en) 2017-06-16 2023-01-24 The Regents Of The University Of California Conjugates of active pharmaceutical ingredients
CN107417706B (zh) * 2017-08-04 2019-07-16 大连理工大学 具有光、声敏活性的二氢卟吩青蒿琥酯结合物及其制备方法与应用
US11612681B2 (en) * 2017-09-06 2023-03-28 The Research Foundation For The State University Of New York Compositions and devices for removal of endotoxins and cytokines from fluids
WO2019236769A1 (en) * 2018-06-05 2019-12-12 University Of Mississippi Medical Center Production of sized macro- and micro- elp particles for drug delivery
US20210346518A1 (en) * 2018-08-31 2021-11-11 The Regents Of The University Of California Cyanine-based telodendrimers and uses for treating cancer
CN109253993B (zh) * 2018-10-25 2021-03-23 中国石油大学(华东) 纳米荧光探针及其制备方法和应用
US20220023290A1 (en) * 2018-11-20 2022-01-27 Starpharma Pty Ltd Therapeutic dendrimer
AU2019390489B2 (en) * 2018-11-29 2023-08-17 Starpharma Pty Ltd Dendrimer for therapy and imaging
US12337004B2 (en) 2019-04-27 2025-06-24 Health Research, Inc. Coumarin-modified androgens for the treatment of prostate cancer
CN110591075B (zh) * 2019-06-28 2022-03-04 四川大学华西医院 一种PEG-Peptide线性-树状给药系统及其制备方法和用途
CN110292633B (zh) * 2019-08-01 2021-09-03 深圳市老年医学研究所 一种基于共价自组装方式构建的具有光动力学性能的纳米胶囊及其检测方法
CN110804190B (zh) * 2019-11-05 2021-10-29 东莞行渡科技有限公司 嵌入芳酰胺片段的亲疏水分子自组装胶束及超分子光催化组装体的制备方法
JP2023507617A (ja) * 2019-12-17 2023-02-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脳腫瘍を治療するための架橋ナノセラノスティクスにおけるシーケンシャルターゲティング
US20240293588A1 (en) * 2020-06-03 2024-09-05 Starpharma Pty Ltd Therapeutic conjugates
CN111607101A (zh) * 2020-06-29 2020-09-01 南京大学 一种具有活性氧响应性的树状大分子及其制法和用途
CN114848852B (zh) * 2021-01-20 2023-04-28 中国科学院精密测量科学与技术创新研究院 一种自组装石墨烯量子点纳米粒子及其制备方法及其应用
CN112964683B (zh) * 2021-02-08 2022-06-17 山西医科大学 叶酸修饰氮掺杂石墨烯量子点/银纳米荧光探针的制备方法和应用
CN115192705B (zh) * 2021-04-13 2023-10-13 中国科学院化学研究所 一种两性离子共价有机聚合物/二氧化钛纳米复合材料及其制备方法和应用
CN113248753B (zh) * 2021-05-11 2022-04-22 中南大学湘雅医院 一种羟基蒽醌体外循环改性膜的制备方法
KR102697416B1 (ko) * 2021-05-20 2024-08-21 성균관대학교산학협력단 옥살레이트계 화합물을 포함하는 초음파 기반의 항암 면역치료용 고분자 복합체 및 이의 제조방법
CN114788863A (zh) * 2022-03-16 2022-07-26 苏州深得源健康科技有限公司 一种制备卟啉锌纳米空心球的方法及其应用
CN115518156B (zh) * 2022-10-12 2023-10-10 西安交通大学医学院第二附属医院 一种响应性释放近红外光热剂的纳米复合物、制备方法及应用
CN116606297B (zh) * 2023-04-07 2024-11-26 井冈山大学 一类尾式苯丙氨酸卟啉衍生物的合成方法和应用
CN118852184B (zh) * 2024-09-26 2025-01-28 浙江浙能技术研究院有限公司 一种具有装载和靶向释放喜树碱类药物的超分子材料及其制备方法和应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002962A (en) * 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
CN1310612A (zh) 1998-05-20 2001-08-29 利普索姆公司 新型颗粒制剂
US6310043B1 (en) 1998-08-07 2001-10-30 Governors Of The University Of Alberta Treatment of bacterial infections
JP4260370B2 (ja) 1998-08-10 2009-04-30 旭化成ファーマ株式会社 塩酸ファスジルの経口徐放性製剤
ATE283271T1 (de) * 1998-08-28 2004-12-15 Destiny Pharma Ltd Porphyrin derivate, ihre verwendung in der photodynamischen therapie und diese enthaltende medizinische geräte
US6365191B1 (en) 1999-02-17 2002-04-02 Dabur Research Foundation Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof
JP4659937B2 (ja) 1999-11-19 2011-03-30 ナノキャリア株式会社 コア−シェル構造のポリイオンコンプレックスミセル
US20020041898A1 (en) 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
US6638924B2 (en) 2000-08-30 2003-10-28 Pharmacyclics, Inc. Metallotexaphyrin derivatives
US6797727B2 (en) 2001-07-16 2004-09-28 Transition Therapeutics Inc. Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
AU2002953073A0 (en) 2002-11-21 2003-01-16 Access Pharmaceuticals Australia Pty Limited Amplification of biotin-mediated targeting
TW201424770A (zh) 2003-02-14 2014-07-01 Childrens Hosp & Res Ct Oak 親脂藥物傳送媒介物及其使用方法
JP3953037B2 (ja) 2004-03-10 2007-08-01 独立行政法人科学技術振興機構 多数の人工光合成反応中心を有する亜鉛ポルフィリンデンドリマーとピリジルナフタレンジイミドとの超分子錯体
US8153111B2 (en) * 2004-06-18 2012-04-10 Ceramoptec Industries, Inc. Photo-triggered release of active substances from dendrimer-photosensitizer complexes
KR100578382B1 (ko) 2004-07-16 2006-05-11 나재운 항암제의 전달체용 수용성 키토산 나노입자 및 그 제조방법
US20060127467A1 (en) 2004-12-14 2006-06-15 Watkin Kenneth L Nanoparticles for delivery of therapeutic agents using ultrasound and associated methods
WO2006089156A2 (en) 2005-02-16 2006-08-24 Rutgers, The State University Drug-polymer conjugates coupled to a peptidic carrier
CU23556A1 (es) 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
WO2007084126A1 (en) 2006-01-19 2007-07-26 Allexcel, Inc. Solubilization and targeted delivery of drugs with self-assembling amphiphilic polymers
WO2008034120A2 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Lysine-based polymeric linkers
WO2008062909A1 (en) 2006-11-22 2008-05-29 The University Of Tokyo ENVIRONMENT-RESPONDING siRNA CARRIER USING DISULFIDE-BRIDGED POLYMERIC MICELLE
US20100008938A1 (en) 2007-01-22 2010-01-14 Anil Diwan Self assembling amphiphilic polymers as antiviral agents
WO2008091247A1 (en) 2007-01-23 2008-07-31 Elio Paul A Tube recliner mechanism and seat
WO2009123934A2 (en) 2008-03-29 2009-10-08 Emory University Branched multifunctional nanoparticle conjugates and their use
WO2009155335A2 (en) 2008-06-19 2009-12-23 University Of Maryland, Baltimore Conjugates of 19f mr imaging tracers and chemotherapeutic agents for drug quantification and drug dose individualization
CN102159189B (zh) 2008-09-23 2013-06-12 加利福尼亚大学董事会 用于药物递送的纳米载体
US9296988B2 (en) 2009-06-19 2016-03-29 The Regents Of The University Of California Three-dimensional cell adhesion matrix
KR101793082B1 (ko) 2009-09-24 2017-11-02 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 방광암 특이적 리간드 펩티드
EP2488206B1 (en) 2009-10-16 2018-03-21 University Health Network (UHN) Porphyrin nanovesicles
US8945513B2 (en) 2011-03-18 2015-02-03 International Business Machines Corporation Star polymer nanoshells and methods of preparation thereof
US10106650B2 (en) 2011-05-13 2018-10-23 The Regents Of The University Of California Reversibly crosslinked micelle systems
CN107652438B (zh) 2011-12-21 2021-10-12 加利福尼亚大学董事会 药物递送增强的末端树枝状聚合物
US8895055B2 (en) 2011-12-21 2014-11-25 The Regents Of The University Of California Telodendrimer nanodiscs without apolipoprotein
US9642916B2 (en) 2012-12-12 2017-05-09 The Regents Of The University Of California Porphyrin modified telodendrimers
US11406714B2 (en) 2013-08-21 2022-08-09 The Research Foundation For The State University Of New York Telodendrimers and nanocarriers and methods of using same
WO2016172635A1 (en) 2015-04-24 2016-10-27 The Regents Of The University Of California Nanoporphyrin telodendrimers for treatment of vascular abnormalities
US11369614B2 (en) 2017-01-19 2022-06-28 The Research Foundation For The State University Of New York Telodendrimers with riboflavin moieties and nanocarriers and methods of making and using same
US11612681B2 (en) 2017-09-06 2023-03-28 The Research Foundation For The State University Of New York Compositions and devices for removal of endotoxins and cytokines from fluids

Also Published As

Publication number Publication date
US10238750B2 (en) 2019-03-26
US20160038605A1 (en) 2016-02-11
EP2931290B1 (en) 2018-08-15
US9642916B2 (en) 2017-05-09
EP2931290A4 (en) 2016-08-24
JP6585504B2 (ja) 2019-10-02
US20140161719A1 (en) 2014-06-12
CN105188717A (zh) 2015-12-23
JP2016511222A (ja) 2016-04-14
US20200046841A1 (en) 2020-02-13
US11219692B2 (en) 2022-01-11
EP2931290A1 (en) 2015-10-21
US20180036417A1 (en) 2018-02-08
WO2014093675A1 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
CN105188717B (zh) 卟啉修饰末端树枝状聚合物
JP6542827B2 (ja) 可逆的に架橋されたミセル系
CN104105508B (zh) 药物递送增强的末端树枝状聚合物
Jenkins et al. Mini-review: fluorescence imaging in cancer cells using dye-doped nanoparticles
CN110392583B (zh) 改进的杂化的末端树枝状聚合物
ES2745745T3 (es) Polipéptidos entrecruzados autoensamblados en forma de estrella y su uso como transportadores en aplicaciones biomédicas
Zhong et al. Rational design and facile fabrication of biocompatible triple responsive dendrimeric nanocages for targeted drug delivery
JP7620321B2 (ja) シアニンベースをベースとするテロデンドリマー及び癌治療のための使用
WO2016172635A1 (en) Nanoporphyrin telodendrimers for treatment of vascular abnormalities
KR20240000677A (ko) 나노-바이오 구조 조절을 기반으로 하는 새로운 고리형 펩티드, 이를 포함하는 코어/쉘 구조의 펩티좀 및 이의 용도
EP4057997B1 (en) Nanoparticles for medical and diagnostic applications
JP6235460B6 (ja) 可逆的に架橋されたミセルｓｙｓｔｅｍｓ
Amreddy et al. Multifunctional dendrimers for theranostic applications
Ambade et al. Dendritic nanostructures for cancer therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant